2. Disease Areas
  3. Neurological, Eye or Ear Disease
  4. CNS Neoplasm

CNS Neoplasm

Neoplasms of the central nervous system (CNS) comprise a diverse group of benign and malignant tumors, with significant advances in understanding their molecular underpinnings offering promise for improved outcomes. Despite these advances, prognosis remains poor for the most aggressive form, glioblastoma multiforme (GBM), particularly in older adults, where median survival rarely exceeds one year. In contrast, pediatric tumors like medulloblastoma have seen improved survival through risk stratification and refined treatments. Continued research in both preclinical and clinical settings is essential to achieve long-term control and potential cures. The integration of multidisciplinary care and close collaboration between clinicians and tumor biologists is strengthening the outlook for neuro-oncology, making the future increasingly hopeful.

 

CNS Neoplasm (138):

Cat. No. Nombre del producto No. CAS Pureza Estructura química
  • HY-15676
    Idasanutlin 1229705-06-9 99.93%
    Idasanutlin (RG7388) is an orally bioavailable MDM2 inhibitor with an IC50 of 6 nM. Idasanutlin disrupts MDM2-p53 binding, stabilizes and activates p53, triggering cell cycle arrest, apoptosis, and reduced cancer cell viability. Idasanutlin reduces EGFR protein expression and phosphorylation, suppresses downstream SHP2, MEK1/2, ERK1/2, AKT, mTOR, p70(S6K1), and S6 signaling. Idasanutlin induces mitochondrial ROS production, drives p38 MAPK phosphorylation, upregulates NOXA, and mediates caspase-3-dependent apoptosis and gasdermin E-mediated pyroptosis. Idasanutlin can be used for the research of TP53-mutant non-small cell lung cancer, T-cell acute lymphoblastic leukemia, colorectal carcinoma, melanoma, diffuse large B-cell lymphoma, mantle cell lymphoma, non-Hodgkin lymphoma, severe fever with thrombocytopenia syndrome, neuroblastoma, acute lymphoblastic leukemia, relapsed or refractory acute myeloid leukemia, osteosarcoma, solid tumors, and hematological tumors.
    Idasanutlin
  • HY-14909
    Bardoxolone 218600-44-3 99.50%
    Bardoxolone (CDDO; RTA 401) is a Nrf2 activator. Bardoxolone shows anti-SARS-CoV-2 3CLpro with IC50 of 27.99 μM. Bardoxolone activates the Nrf2 pathway and inhibits the NF-κB pathway. Bardoxolone can induce cells differentiation, apoptosis and shows antiproliferative activity against cancer cells. Bardoxolone can increase ROS and decrease intracellular GSH levels. Bardoxolone inhibits Z-VAD-FMK (HY-16658B)-induced necroptosis. Bardoxolone can be used for the research of cancer, inflammation and infection, such as SARS-CoV infection and glioblastoma.
    Bardoxolone
  • HY-P99042
    Polatuzumab 2279068-37-8 99.69%
    Polatuzumab is a monoclonal antibody that targets CD79b on the surface of B cells. Polatuzumab can be used to synthesize the ADC Polatuzumab Vedotin (HY-132253), which has anti-tumor activity.
    Polatuzumab
  • HY-B0208
    Methimazole 60-56-0 99.97%
    Methimazole (Thiamazole) is an anti-thyroid agent, which blocks thyroid hormone production from the thyroid gland. Metamizol can cause hepatotoxicity.
    Methimazole
  • HY-50722
    NNC 55-0396 357400-13-6 98.43%
    NNC 55-0396 (NNC 55-0396 dihydrochloride) is a blood-brain-barrier-permeable T-type Ca2+ channel inhibitor and pan-P450 inhibitor. NNC 55-0396 selectively inhibits T-type Ca2+ channels, suppresses HIF-1α expression and stability and inhibits Kv currents. NNC 55-0396 reduces brain infarct and attenuates neurological dysfunction. NNC 55-0396 inhibits the activity of multiple P450 enzymes. NNC 55-0396 (free base) can be used for the research of brain injury, hypertension, and glioblastoma.
    NNC 55-0396
  • HY-Q66655
    YRDC-IN-1 3120494-74-5
    YRDC-IN-1 is a blood-brain barrier-permeable YRDC inhibitor. YRDC is a key enzyme that catalyzes the formation of N6-threonylcarbamoyladenosine at position 37 of tRNA (t6A37). YRDC-IN-1 selectively inhibits the translation of ANN codon-enriched FABP7, thereby reducing lipid droplet formation, increasing ROS, and reversing the acquired resistance of GBM to Temozolomide (TMZ) (HY-17364). YRDC-IN-1 can be used for the research of glioblastoma.
    YRDC-IN-1
  • HY-W010480
    Toluquinone 553-97-9
    Toluquinone is a Toluquinol analogue. Toluquinone shows lower growth inhibitory activity against a panel of cancer cell lines of breast adenocarcinoma, promyelocytic leukemia, glioblastoma, fibrosarcoma, and colorectal adenocarcinoma than Toluquinol.
    Toluquinone
  • HY-181311
    CCT400028 98.03%
    CCT400028 is a PROTACs-class degrader that targets the Aurora A (AURKA) kinase. CCT400028 induces ubiquitination and proteasomal degradation of target proteins by recruiting the cereblon (CRBN) E3 ubiquitin ligase. The KD values of CCT400028 against the three subtypes of human AURKA are 71 nM, 2100 nM and >10000 nM, respectively, and its IC50 against human CRBN is 6300 nM. CCT400028 is applicable to relevant research on leukemia, neuroblastoma and glioma.
    CCT400028
  • HY-Y0850
    Polyvinyl alcohol (Mw 146000-186000, 99+% hydrolyzed) 9002-89-5 99.60%
    Polyvinyl alcohol (Mw 146000-186000, 99+% hydrolyzed) is a non-biodegradable, hydrophilic, odorless biomedical polymer with cell adhesion/proliferation inhibition, peripheral nerve regeneration induction, dissolution enhancement, and non-toxic, biocompatible properties.
    Polyvinyl alcohol (Mw 146000-186000, 99+% hydrolyzed)
  • HY-12494
    LDC1267 1361030-48-9 99.64%
    LDC1267 is a AXL/TAM/FLT3 inhibitor with IC50 values of 42 nM, 130 nM, and 63 nM against AXL, MERTK, and TYRO3, respectively. LDC1267 blocks GAS6-induced AXL phosphorylation and the downstream AKT/ERK1/2 signaling pathway. LDC1267 inhibits cancer cell proliferation, colony formation, and glioblastoma cell invasion, without causing obvious impairment of cytotoxic autophagic flux. LDC1267 exerts a synergistic effect when used in combination with Imatinib (HY-15463) in chronic myeloid leukemia models. LDC1267 can be widely applied in studies related to glioblastoma and chronic myeloid leukemia.
    LDC1267
  • HY-108852
    Basiliximab 179045-86-4 ≥99.0%
    Basiliximab (CHI 621) is a recombinant chimeric murine/human IgG1 monoclonal anti-interleukin-2 receptor antibody. Basiliximab can be used for the research of renal transplantation.
    Basiliximab
  • HY-16397
    Phenformin 114-86-3 98.02%
    Phenformin (Phenethylbiguanide) is an orally active biguanide hypoglycemic agent. Phenformin inhibits mitochondrial respiratory chain complex I, leading to an increased AMP/ATP ratio, activation of AMPK, and subsequent inhibition of the mTOR pathway, thereby suppressing cell proliferation, inducing apoptosis and autophagy. Phenformin inhibits cancer stem cells (CSCs) and possesses potent antitumor potential.
    Phenformin
  • HY-100685
    MS-444 150045-18-4 99.42%
    MS-444 (BE-34776) is a HuR (ELAVL1) inhibitor that blocks the cytoplasmic translocation of HuR and inhibits its dimerization. MS-444 reduces cytoplasmic HuR levels by preventing the binding of HuR to ARE-mRNA, without altering the total expression of HuR. MS-444 induces apoptosis, inhibits cell growth, angiogenesis and invasion, and also regulates immune function and microbiota. MS-444 effectively alters the number, size and invasiveness of tumors in various cancer models. MS-444 is tolerable to intraperitoneal injection in vivo and can be applied to research related to colorectal cancer, familial adenomatous polyposis, colitis-associated cancer and glioblastoma.
    MS-444
  • HY-131031
    KCC-07 315702-75-1 99.97%
    KCC-07 is a potent and brain-penetrant MBD2 (methyl-CpG-binding domain protein 2) inhibitor. KCC-07 prevents binding of MBD2 to methylated DNA and activates brain specific angiogenesis inhibitor 1 (BAI1) inducing anti-proliferative BAI1/p53/p21 signaling. KCC-07 is a TRACER (transcriptional regulation via active control of epigenetic reprogramming) that can stimulate ER transcriptional activity. KCC-07 can be used for the stduy of breast cancer.
    KCC-07
  • HY-W011725
    N-6-Methyl-2-deoxyadenosine 2002-35-9 99.83%
    N-6-Methyl-2-deoxyadenosine (m6dA) is an adenine nucleoside analogue. N-6-Methyl-2-deoxyadenosine targets nuclear processes and DNA replication machineries including WER, SATB1, TFAM, Jumu, SSBP1, DNA polymerase η and phage polymerase Gp90 exo−. N-6-Methyl-2-deoxyadenosine acts as a multifunctional epigenetic regulator that modulates transcription, DNA damage response, cell cycle, transposon silencing, stress adaptation, epigenetic crosstalk, and nucleosome organization in both prokaryotes and eukaryotes. N-6-Methyl-2-deoxyadenosine regulates mitochondrial epigenetic inheritance and is required for fear extinction memory in mice. N-6-Methyl-2-deoxyadenosine exhibits dysregulated levels in cancers. N-6-Methyl-2-deoxyadenosine can be used for the research of glioblastoma, triple negative breast cancer, and conditioned fear (fear extinction impairment).
    N-6-Methyl-2-deoxyadenosine
  • HY-125848
    Ginsenoside F2 62025-49-4 99.92%
    Ginsenoside F2 is an orally active bioactive compound that participates in the regulation of metabolism and inflammation. Ginsenoside F2 promotes the phosphorylation of AMPK and ACC, binds to PPARγ, inhibits the phosphorylation of MAPK, activates the PI3K/AKT/GSK-3β pathway, reduces GLRX expression, and regulates lipid metabolism. Ginsenoside F2 reduces ROS production and MDA levels, restores SOD activity in cells, and alleviates oxidative stress. Ginsenoside F2 induces cell apoptosis (Apoptosis) and increases the number of cleaved caspase-3-positive cells. Ginsenoside F2 reduces body weight gain, adipose tissue weight and serum lipid levels in obese mice, and activates the hepatic AMPK signaling pathway and the expression of antioxidant enzymes. Ginsenoside F2 alleviates atopic dermatitis in mice by inhibiting inflammation and reshaping the gut microbiota. Ginsenoside F2 is applicable to research related to insulin resistance, obesity, atopic dermatitis, liver cancer, glioblastoma and glioma.
    Ginsenoside F2
  • HY-W017982
    CMIT/MIT (14.5% in water) 55965-84-9
    CMIT/MIT is a CMIT and MIT mixture. CMIT and MIT are powerful synthetic biocidal substances. CMIT and MIT are used as preservatives in various cosmetics and industrial products. CMIT and MIT are present in many water-soluble consumer products, such as shampoos, toothpastes. CMIT/MIT (3:1 mixture of CMIT and MIT) produces mitochondrial ROS via inhibiting mitochondrial complex I and II. CMIT/MIT (in 3:1 ratio) induces neurotoxicity through the upregulation of the MAPKs signaling pathways. CMIT/MIT can be used in the research of respiratory diseases and neuroblastoma.
    CMIT/MIT (14.5% in water)
  • HY-D1668
    Biotin-11-dCTP 99.1%
    Biotin-11-dCTP is a biotinylated deoxynucleoside triphosphate and an important DNA labeling reagent. In random primer DNA labeling reactions, Biotin-11-dCTP incorporates into newly synthesized DNA strands to generate labeled DNA probes suitable for hybridization applications. In addition, Biotin-11-dCTP can serve as a substrate for terminal deoxynucleotidyl transferase to end-label oligonucleotides for telomere sequence detection, or to label the cut ends of linearized DNA molecules, thereby supporting streptavidin-based electron microscopy analysis. For example, Biotin-11-dCTP can label the cut ends of linearized DNA molecules under the action of dGTP and avian myeloblastosis virus reverse transcriptase.
    Biotin-11-dCTP
  • HY-W019724
    2,2-Dihydroxyacetic acid 563-96-2 98.0%
    2,2-Dihydroxyacetic acid is an endogenous metabolite, which is the monohydrate of Glyoxylic Acid. 2,2-Dihydroxyacetic acid may participate in the microbial glyoxylate cycle, induce an increase in reactive oxygen species, promote cell differentiation, and modify proteins to form advanced glycation end products (AGEs) (HY-NP165). 2,2-Dihydroxyacetic acid is associated with metabolic diseases such as primary hyperoxaluria.
    2,2-Dihydroxyacetic acid
  • HY-N0891
    Tubeimoside II 115810-12-3 99.90%
    Tubeimoside II is an orally active triterpenoid saponin and antiviral agent that binds to PACT/PRKRA with Kd values of 5.37 μM and 133.1 μM, respectively. Tubeimoside II inhibits oxidase-dependent EGFR activation and reduces TGF-β1-induced oxidative stress. Tubeimoside II activates the RIG-I signaling pathway and increases IFN-β secretion. Tubeimoside II suppresses TPA-induced ear edema, mouse sarcoma 180 growth, and TPA-induced skin tumor formation. Tubeimoside II exerts broad-spectrum antiviral activity against SARS-CoV-2, HCoV-OC43, and IAV-H1N1/FM1. Tubeimoside II can be used in research related to retinoblastoma, respiratory viral infections, skin tumors, and sarcoma 180.
    Tubeimoside II